Surgery for advanced and metastatic pancreatic cancer--current state and trends

Standard

Surgery for advanced and metastatic pancreatic cancer--current state and trends. / Nentwich, Michael F; Bockhorn, Maximilian; König, Alexandra; Izbicki, Jakob R; Cataldegirmen, Güllü.

In: ANTICANCER RES, Vol. 32, No. 5, 01.05.2012, p. 1999-2002.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Nentwich, MF, Bockhorn, M, König, A, Izbicki, JR & Cataldegirmen, G 2012, 'Surgery for advanced and metastatic pancreatic cancer--current state and trends', ANTICANCER RES, vol. 32, no. 5, pp. 1999-2002.

APA

Nentwich, M. F., Bockhorn, M., König, A., Izbicki, J. R., & Cataldegirmen, G. (2012). Surgery for advanced and metastatic pancreatic cancer--current state and trends. ANTICANCER RES, 32(5), 1999-2002.

Vancouver

Nentwich MF, Bockhorn M, König A, Izbicki JR, Cataldegirmen G. Surgery for advanced and metastatic pancreatic cancer--current state and trends. ANTICANCER RES. 2012 May 1;32(5):1999-2002.

Bibtex

@article{384c3ccefc79431faba6358bf64ac853,
title = "Surgery for advanced and metastatic pancreatic cancer--current state and trends",
abstract = "Due to the late onset of symptoms in pancreatic cancer, patients are often presented with an already advanced or metastatic state of disease. Only in a minority of patients is a tumor resection indicated, e.g. in general tumor encasement of major vessels, while the presence of metastatic disease excludes patients from curative-intended surgery. Limitations for pancreatic resections have been debated and re-thought after more experience has gained over time. This holds true for en-bloc vascular resections, total pancreatectomies, intentional R2 pancreatic resections and synchronous resection of liver metastases. These issues are addressed in this review.",
keywords = "Humans, Liver Neoplasms, Neoplasm Metastasis, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms",
author = "Nentwich, {Michael F} and Maximilian Bockhorn and Alexandra K{\"o}nig and Izbicki, {Jakob R} and G{\"u}ll{\"u} Cataldegirmen",
year = "2012",
month = may,
day = "1",
language = "English",
volume = "32",
pages = "1999--2002",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

RIS

TY - JOUR

T1 - Surgery for advanced and metastatic pancreatic cancer--current state and trends

AU - Nentwich, Michael F

AU - Bockhorn, Maximilian

AU - König, Alexandra

AU - Izbicki, Jakob R

AU - Cataldegirmen, Güllü

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Due to the late onset of symptoms in pancreatic cancer, patients are often presented with an already advanced or metastatic state of disease. Only in a minority of patients is a tumor resection indicated, e.g. in general tumor encasement of major vessels, while the presence of metastatic disease excludes patients from curative-intended surgery. Limitations for pancreatic resections have been debated and re-thought after more experience has gained over time. This holds true for en-bloc vascular resections, total pancreatectomies, intentional R2 pancreatic resections and synchronous resection of liver metastases. These issues are addressed in this review.

AB - Due to the late onset of symptoms in pancreatic cancer, patients are often presented with an already advanced or metastatic state of disease. Only in a minority of patients is a tumor resection indicated, e.g. in general tumor encasement of major vessels, while the presence of metastatic disease excludes patients from curative-intended surgery. Limitations for pancreatic resections have been debated and re-thought after more experience has gained over time. This holds true for en-bloc vascular resections, total pancreatectomies, intentional R2 pancreatic resections and synchronous resection of liver metastases. These issues are addressed in this review.

KW - Humans

KW - Liver Neoplasms

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Pancreatectomy

KW - Pancreatic Neoplasms

M3 - SCORING: Journal article

C2 - 22593478

VL - 32

SP - 1999

EP - 2002

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 5

ER -